Ezetimibe--a new approach in hypercholesterolemia management.

Effect of ezetimibe on insulin secretion in db/db diabetic mice. Exp Diabetes Res (2012) 0.80

Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep (2013) 0.76

Polymorphisms of the Niemann-Pick C1-like 1 gene in a Japanese population. Biomed Rep (2012) 0.75

Ezetimibe - a new approach in hypercholesterolemia management. Pharmacol Rep (2012) 0.75

The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75

Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep (2010) 1.56

Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis (2014) 1.39

[Autoimmune polyglandular syndrome type 2 in pregnancy: a case report]. Przegl Lek (2013) 0.97

Focal lesions in the ultrasonographic examination of the spleen as a symptom of various disease statuses: literature survey and case descriptions. Med Sci Monit (2006) 0.95

Metformin increases phagocytosis and acidifies lysosomal/endosomal compartments in AMPK-dependent manner in rat primary microglia. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.92

AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) increases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures. Neurotoxicology (2009) 0.92

Growth hormone therapy in children and adults. Pharmacol Rep (2007) 0.91

Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep (2010) 0.89

Bile bacterial flora and its in vitro resistance pattern in patients with acute cholangitis resulting from choledocholithiasis. Scand J Gastroenterol (2011) 0.87

Ambivalent effects of compound C (dorsomorphin) on inflammatory response in LPS-stimulated rat primary microglial cultures. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.86

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye? Eur J Intern Med (2013) 0.86

Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep (2005) 0.85

Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep (2008) 0.85

Immunophilin ligands decrease release of pro-inflammatory cytokines (IL-1beta, TNF-alpha and IL-2 in rat astrocyte cultures exposed to simulated ischemia in vitro. Pol J Pharmacol (2004) 0.84

A successful case of pain management using metformin in a patient with adiposis dolorosa. Int J Clin Pharmacol Ther (2013) 0.83

The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia. Endokrynol Pol (2011) 0.82

[Peripheral precocious puberty]. Endokrynol Pol (2009) 0.82

Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders. Neuro Endocrinol Lett (2012) 0.82

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.81

Eplerenone promotes alternative activation in human monocyte-derived macrophages. Pharmacol Rep (2013) 0.80

Update on the management of polycystic ovary syndrome. Pharmacol Rep (2006) 0.80

Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course. Pol Przegl Chir (2013) 0.80

Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep (2010) 0.79

[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report]. Pol Arch Med Wewn (2007) 0.79

Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure. Pharmacol Rep (2011) 0.79

[Incidentaloma--one of the greatest challenges of modern endocrinology]. Pol Merkur Lekarski (2006) 0.79

[Diagnostic difficulties in diagnosis of splenic abscesses]. Wiad Lek (2007) 0.79

Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep (2013) 0.79

Controlling newly diagnosed type 2 diabetes mellitus with metformin managed pain symptoms in a patient affected with Dercum's disease. Pain Med (2012) 0.79

[Atypical pituitary tumors]. Pol Merkur Lekarski (2012) 0.79

Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis. Int Immunopharmacol (2010) 0.79

AMP-activated protein kinase is involved in induction of protective autophagy in astrocytes exposed to oxygen-glucose deprivation. Cell Biol Int (2014) 0.78

[Designing and optimization of real-time RT-PCR technique for the detection of hepatitis C virus (HCV) genome in blood serum as internal laboratory quality control]. Przegl Epidemiol (2011) 0.78

Role of the SOCS in monocytes/macrophages-related pathologies. Are we getting closer to a new pharmacological target? Pharmacol Rep (2012) 0.78

SOCS and diabetes--ups and downs of a turbulent relationship. Cell Biochem Funct (2013) 0.78

[Central precocious puberty]. Endokrynol Pol (2009) 0.78

Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose. Basic Clin Pharmacol Toxicol (2010) 0.78

Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep (2013) 0.78

Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. Eur J Pharmacol (2014) 0.78

The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynol Pol (2010) 0.78

Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep (2013) 0.78

[The role of TLR4 receptor in development of inflammation and carcinogenesis in ulcerative colitis and pharmacotherapy of this disorder]. Wiad Lek (2013) 0.77

Methionine-enkephalin and leucine-enkephalin increase interleukin-1 beta release in mixed glia cultures. Neuropeptides (2002) 0.77

[Subclinical hypothyroidism]. Wiad Lek (2008) 0.77

[Primary hyperparathyroidism]. Pol Arch Med Wewn (2005) 0.77

[Lipodystrophy: a new insight into an old disease]. Przegl Lek (2012) 0.77

[Subclinical hyperthyroidism]. Endokrynol Pol (2008) 0.77

Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results. Ups J Med Sci (2010) 0.77

Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacol Rep (2011) 0.77

Immunosuppressant cytoprotection correlates with HMGB1 suppression in primary astrocyte cultures exposed to combined oxygen-glucose deprivation. Pharmacol Rep (2011) 0.77

[Adrenal insufficiency]. Wiad Lek (2012) 0.76

The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia. Endokrynol Pol (2014) 0.76

The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol (2011) 0.76

[Atypical clinical presentation of autoimmune polyglandular syndrome type 4]. Przegl Lek (2011) 0.76

A Novel, Highly Selective RT-QPCR Method for Quantification of MSRV Using PNA Clamping Syncytin-1 (ERVWE1). Mol Biotechnol (2015) 0.76

The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Endokrynol Pol (2010) 0.76

Short-term antihypertensive therapy lowers the C-reactive protein level. Postepy Hig Med Dosw (Online) (2012) 0.76

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep (2010) 0.76

[Adipose tissue: a new endocrine organ]. Przegl Lek (2005) 0.76

Hormonal supplementation in endocrine dysfunction in critically ill patients. Pharmacol Rep (2007) 0.76

The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75

[Right atrial tumour and right ventricular failure - diagnostic role of echocardiography and cardiovascular magnetic resonance]. Kardiol Pol (2010) 0.75

[Selected endocrine abnormalities in eating disorders]. Wiad Lek (2010) 0.75

[Normoaldosterone spironolactone sensitive hypertension--a case report]. Pol Arch Med Wewn (2005) 0.75

[Postpartum thyroiditis: current views on unappreciated disease]. Endokrynol Pol (2008) 0.75

[Current views on the role of dehydroepiandrosterone in physiology, pathology and therapy]. Pol Merkur Lekarski (2008) 0.75

[Etiology, histopathological picture and clinical presentation of craniopharyngioma]. Pol Merkur Lekarski (2008) 0.75

Postpartum hypothalamic dysfunction--a case report. Endokrynol Pol (2010) 0.75

[Thyroid hormone resistance syndrome]. Pol Merkur Lekarski (2006) 0.75

[Inhibitory effect of carbamazepine on hypotensive action of spironolactone in primary aldosteronism]. Endokrynol Pol (2009) 0.75

[Growth hormone deficiency in adults]. Przegl Lek (2007) 0.75

[A role of kallikrein-kinin system in gut diseases]. Wiad Lek (2005) 0.75

[Adrenal disorders in pregnancy]. Endokrynol Pol (2009) 0.75

[Adrenopause]. Pol Merkur Lekarski (2008) 0.75

[Advance in treatment of polycystic ovary syndrome]. Pol Merkur Lekarski (2005) 0.75

Subdural hematoma in a patient with Hageman trait--case report. Neurol Med Chir (Tokyo) (2005) 0.75

[Rare disorders of glucocorticoid production, metabolism and action]. Przegl Lek (2009) 0.75

[Hyperprolactinaemia--like symptoms in Wilson's disease]. Pol Merkur Lekarski (2008) 0.75

[Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency]. Pol Merkur Lekarski (2006) 0.75

[Prolactinoma]. Przegl Lek (2009) 0.75

[Rare congenital defects of adrenal steroidogenesis]. Endokrynol Pol (2008) 0.75

[Somatopause: the present state-of-art]. Wiad Lek (2009) 0.75

Atypical clinical manifestation of antiphospholipid syndrome. Pol Arch Med Wewn (2009) 0.75

[Pituitary disorders in pregnancy and after delivery]. Przegl Lek (2010) 0.75

[Usage of beta-adrenolytic agents in patients with chronic pulmonary obstructive disease]. Pol Merkur Lekarski (2008) 0.75

Atypical clinical manifestations of multiple endocrine neoplasia type 1 syndrome. Pol Arch Med Wewn (2009) 0.75

[Advances in the treatment of acromegaly]. Pol Merkur Lekarski (2008) 0.75

[Medullary thyroid cancer - the present state of art]. Endokrynol Pol (2008) 0.75

[An unusual clinical presentation of the autoimmune polyendocrine syndrome]. Pol Arch Med Wewn (2005) 0.75

[Nephrogenic diabetes insipidus induced by colchicine--a case report]. Pol Arch Med Wewn (2005) 0.75

Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment. Pharmacol Rep (2009) 0.75

[Veno-occlusive disease of the liver]. Wiad Lek (2009) 0.75

Potential benefit of paracetamol administration in adult-onset Still's disease. Pol Arch Med Wewn (2009) 0.75

[Modern pharmacotherapy of benign prostatic hyperplasia]. Pol Merkur Lekarski (2005) 0.75

[Prostate cancer chemoprevention]. Przegl Lek (2005) 0.75